{
    "2020-10-29": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Earnings Preview: AbbVie",
                "features": {
                    "keywords": [
                        "Earnings",
                        "Preview",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Acquires",
                        "Gene Therapy",
                        "Moderna",
                        "Japanese Vaccine",
                        "Supply Deal"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQâ„¢ (upadacitinib) in Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Pivotal Phase 3",
                        "RINVOQ",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}